On September 12, 2019 Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) reported it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX "Daiichi Sankyo" (hereafter, new formulation) (Press release, Daiichi Sankyo, SEP 12, 2019, View Source [SID1234539458]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.
It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).
The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.
Product Name
Therapeutic
Category
Original Brand Name
Oxycodone Extended Release Tablets 5mg NX "Daiichi Sankyo"
Oxycodone Extended Release Tablets 10mg NX "Daiichi Sankyo"
Oxycodone Extended Release Tablets 20mg NX "Daiichi Sankyo"
Oxycodone Extended Release Tablets 40mg NX "Daiichi Sankyo"
Sustained cancer
pain treatment
OxyContin TR Tablets 5 mg
OxyContin TR Tablets 10 mg
OxyContin TR Tablets 20 mg
OxyContin TR Tablets 40 mg
About Daiichi Sankyo Opioid Analgesics in Japan
Daiichi Sankyo aims to contribute to the total care of cancer patients for their lives with our opioid analgesics.
Daiichi Sankyo believes that expanding our product lineup of opioid analgesics provides support for patients living with cancer by improving their quality of life through pain relief.
Opioid analgesics sold in Japan by Daiichi Sankyo comprise the hydromorphone hydrochloride formulations Narusus Tablets (extended release formulation), Narurapid Tablets (immediate release formulation), Naruvein Injection (injection formulation), the oxycodone hydrochloride formulations Oxycodone Extended Release Tablets "Daiichi Sankyo" (extended release formulation) and Oxycodone Extended Release Tablets NX "Daiichi Sankyo" (extended release formulation) that have just been launched, Oxycodone Tablets "Daiichi Sankyo" (extended release formulation) and Oxycodone Injections "Daiichi Sankyo"(injection formulation) as well as the fentanyl citrate tape formulation Fetanyl Citrate Tape for 1 day "Daiichi Sankyo" (transdermal absorption formulation).